US to accelerate authorization of COVID-19 vaccines redesigned for omicron

The U.S. is preparing to expedite the authorization of COVID-19 vaccines redesigned to target the omicron variant, The Wall Street Journal reported Dec. 5.

Advertisement

FDA officials met with drugmakers to discuss guidelines for the data the agency will need to quickly assess the revamped vaccines’ safety and efficacy, according to the report.

Federal regulators said Dec. 5 omicron cases have been discovered in 16 states. Preliminary data emerging from South Africa has suggested the variant causes less severe illness than its predecessors.

Advertisement

Next Up in Pharmacy

  • The number of active drug shortages has declined sharply since June, according to the FDA’s drug shortage database. Seventy-five drugs…

  • From payer shifts to regulatory milestones, GLP-1 therapies for obesity and diabetes continued to reshape the healthcare landscape in December.…

  • In 2025, the FDA approved 73 first-time generic drugs.  Here are the generics and their indication, in order of approval…

Advertisement

Comments are closed.